4basebio and Genezen collaboration
Analysis based on 7 articles · First reported Aug 26, 2026 · Last updated Aug 26, 2026
The collaboration is expected to strengthen 4basebio's commercial position by expanding access to its synthetic DNA technology through Genezen's manufacturing network, potentially increasing demand for its products. For Genezen, the partnership enhances its service offerings with innovative DNA technology, likely improving its competitive standing in the gene therapy CDMO market.
4basebio PLC (AIM: 4BB), a Cambridge-based biotechnology company specializing in enzymatically-produced, cell-free DNA, and Genezen, a viral vector contract development and manufacturing organization (CDMO), announced an expanded, non-exclusive collaboration on 26 August 2026. The collaboration provides drug developers access to 4basebio's Research Use Only, High-Quality, and GMP-grade hpDNA development and clinical programs, combined with Genezen's viral vector manufacturing expertise. 4basebio's cell-free DNA manufacturing process eliminates bacterial backbone sequences and antibiotic resistance genes, and in AAV production its hpDNA template demonstrates comparable titers to plasmid DNA while requiring approximately 30% less DNA mass and transfection reagent, reducing costs and improving scalability. The collaboration aims to streamline the path for cell and gene therapy developers to advance programs toward the clinic.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard